Track topics on Twitter Track topics that are important to you
In this interview, filmed in Stockholm at NLSD 2013, Fintan Walton, CEO PharmaVentures talks to Hugh Salter, Head, AstraZeneca Translational Science Center at Karolinska Institutet. They discuss how, by establishing a set of collaborative research programmes focusing on discovering and validating biomarkers, AstraZeneca is developing a toolkit that will sharpen their understanding of diseases and be better able to identify patients suitability for the next generation of treatments.NEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009. it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...